nach oben

Current Osteoporosis Reports

Erschienen in:

01.03.2014 | Regenerative Biology and Medicine in Osteoporosis (EM Schwartz and RE Guldberg, Section Editors)

Local Strategies to Prevent and Treat Osteoporosis

verfasst von: F. Brennan Torstrick, Robert E. Guldberg

Erschienen in: Current Osteoporosis Reports | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Despite advances in systemic osteoporosis therapeutic outcomes, management of fragility fractures and implant fixation in osteoporotic bone remain difficult clinical challenges. Low initial bone density and a prolonged healing response can lead to fracture nonunion and aseptic implant loosening. Local treatment strategies could be used to prevent fracture, accelerate healing, and increase implant fixation by locally stimulating anabolic pathways or inhibiting catabolic pathways. Local strategies under investigation include direct drug release from injectable materials or implant surface coatings. Common locally delivered drugs include bisphosphonates, parathyroid hormone, and bone morphogenetic proteins, yet additional compounds targeting novel pathways in bone biology are also being actively explored. Mechanical stimulation via low intensity pulsed ultrasound, alone or in combination with drug therapy, may also prove effective to promote local bone healing and implant fixation within osteoporotic bone.

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.PubMedCrossRef

Giannoudis PV, Schneider E. Principles of fixation of osteoporotic fractures. J Bone Joint Surg Br Vol. 2006;88-B(10):1272–8.CrossRef

Hertel R. Fractures of the proximal humerus in osteoporotic bone. Osteoporos Int. 2005;16(2):S65–72.PubMedCrossRef

McKoy BE, An YH. An injectable cementing screw for fixation in osteoporotic bone. J Biomed Mater Res. 2000;53(3):216–20.PubMedCrossRef

Bidwell J, Alvarez M, Hood Jr M, Childress P. Functional impairment of bone formation in the pathogenesis of osteoporosis: The bone marrow regenerative competence. Curr Osteoporos Reports. 2013;11(2):117–25.CrossRef

Zhou S, Greenberger JS, Epperly MW, Goff JP, Adler C, LeBoff MS, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008;7(3):335–43.PubMedCentralPubMedCrossRef

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.PubMedCrossRef

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S-I, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597–602.PubMedCentralPubMedCrossRef

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–76.PubMedCrossRef

10.

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL Receptor-Related Protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–23.PubMedCrossRef

11.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003;22(23):6267–76.PubMedCrossRef

12.

Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391(6665):357–62.PubMedCrossRef

13.

Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002;417(6889):664–7.PubMedCrossRef

14.

Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–21.PubMedCrossRef

15.

Adami S, Libanati C, Boonen S, Cummings SR, Ho P-R, Wang A, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing results from the FREEDOM trial. J Bone Joint Surg. 2012;94(23):2113–9.PubMedCrossRef

16.

Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65.PubMedCrossRef

17.

Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701.PubMedCentralPubMedCrossRef

18.

Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26.PubMedCrossRef

19.

Gelb BD, Shi G-P, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236–8.PubMedCrossRef

20.

Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci. 1998;95(23):13453–8.PubMedCrossRef

21.

Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res. 2010;25(5):937–47.PubMed

22.

Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686–96.PubMedCrossRef

23.

Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–22.PubMedCrossRef

24.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–41.PubMedCrossRef

25.

Kwek EBK, Goh SK, Koh JSB, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of Alendronate therapy? Injury. 2008;39(2):224–31.PubMedCrossRef

26.

Schilcher JMD, Michaëlsson KMDP, Aspenberg PMDP. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364(18):1728–37.PubMedCrossRef

27.

Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for bone and mineral Research. J Bone Miner Res. 2010;25(11):2267–94.PubMedCrossRef

28.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362(19):1761–71.PubMedCrossRef

29.

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004;62(5):527–34.PubMedCrossRef

30.

Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, So Few data. J Oral Maxillofac Surg. 2009;67(5, Supplement):61–70.PubMedCrossRef

31.

Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010; 341.

32.

Schousboe J. Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep. 2013;11(1):21–9.PubMedCrossRef

33.

Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14(3):259–62.PubMed

34.

Wu ZX, Liu D, Wan SY, Cui G, Zhang Y, Lei W. Sustained-release rhBMP-2 increased bone mass and bone strength in an ovine model of postmenopausal osteoporosis. J Orthop Sci. 2011;16(1):99–104.PubMedCrossRef

35.

Liu H, Webster TJ. Ceramic/polymer nanocomposites with tunable drug delivery capability at specific disease sites. J Biomed Mater Res A. 2010;93(3):1180–92.PubMed

36.

Phillips FM, Turner AS, Seim 3rd HB, MacLeay J, Toth CA, Pierce AR, et al. In vivo BMP-7 (OP-1) enhancement of osteoporotic vertebral bodies in an ovine model. Spine J. 2006;6(5):500–6.PubMedCrossRef

37.

McClellan JW, Mulconrey DS, Forbes RJ, Fullmer N. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech. 2006;19(7):483–6.PubMedCrossRef

38.

Zara JN, Siu RK, Zhang X, Shen J, Ngo R, Lee M, et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng A. 2011;17(9–10):1389–99.CrossRef

39.

Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone. 2000;27(4):479–86.PubMedCrossRef

40.

Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J. 2008;8(6):1011–8.PubMedCrossRef

41.

Boerckel JD, Kolambkar YM, Dupont KM, Uhrig BA, Phelps EA, Stevens HY, et al. Effects of protein dose and delivery system on BMP-mediated bone regeneration. Biomaterials. 2011;32(22):5241–51.PubMedCentralPubMedCrossRef

42.

Klazen CAH, Lohle PNM, de Vries J, Jansen FH, Tielbeek AV, Blonk MC, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet. 2010;376(9746):1085–92.PubMedCrossRef

43.

Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009;373(9668):1016–24.PubMedCrossRef

44.

Boonen S, Wahl DA, Nauroy L, Brandi ML, Bouxsein ML, Goldhahn J, et al. Balloon kyphoplasty and vertebroplasty in the management of vertebral compression fractures. Osteoporos Int. 2011;22(12):2915–34.PubMedCrossRef

45.

Panzavolta S, Torricelli P, Bracci B, Fini M, Bigi A. Alendronate and Pamidronate calcium phosphate bone cements: Setting properties and in vitro response of osteoblast and osteoclast cells. J Inorg Biochem. 2009;103(1):101–6.PubMedCrossRef

46.

Sabokbar A, Fujikawa Y, Murray DW, Athanasou NA. Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. Ann Rheum Dis. 1998;57(10):614–8.PubMedCrossRef

47.

Sörensen TC, Arnoldi J, Procter P, Beimel C, Jönsson A, Lennerås M, et al. Locally enhanced early bone formation of zoledronic acid incorporated into a bone cement plug in vivo. J Pharm Pharmacol. 2013;65(2):201–12.PubMedCrossRef

48.•

Matuszewski Ł, Turżańska K, Matuszewska A, Jabłoński M, Polkowska I, Mazurkiewicz T. Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography. Int Orthop. 2013;37(6): 1187–93. Assessed effects of bisphosphonate-enriched bone cement injected into non-OVX rat tibiae.

49.

Yu NY, Ruys AJ, Zenios M, Godfrey C, McDonald M, Kiely P, et al. Bisphosphonate-laden acrylic bone cement: mechanical properties, elution performance, and in vivo activity. J Biomed Mater Res B Appl Biomater. 2008;87(2):482–91.PubMedCrossRef

50.

Musgrave DS, Bosch P, Ghivizzani S, Robbins PD, Evans CH, Huard J. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone. 1999;24(6):541–7.PubMedCrossRef

51.

Fang J, Zhu YY, Smiley E, Bonadio J, Rouleau JP, Goldstein SA, et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci. 1996;93(12):5753–8.PubMedCrossRef

52.

Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat Med. 1999;5(7):753–9.PubMedCrossRef

53.

Bolon B, Carter C, Daris M, Morony S, Capparelli C, Hsieh A, et al. Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis[ast]. Mol Ther. 2001;3(2):197–205.PubMedCrossRef

54.

Egermann M, Schneider E, Evans CH, Baltzer AW. The potential of gene therapy for fracture healing in osteoporosis. Osteoporos Int. 2005;16(2):S120–8.PubMedCrossRef

55.

Evans CH. Gene delivery to bone. Adv Drug Deliv Rev. 2012;64(12):1331–40.PubMedCentralPubMedCrossRef

56.

Bonadio J. Tissue engineering via local gene delivery. J Mol Med (Berl). 2000;78(6):303–11.CrossRef

57.

Peter B, Pioletti DP, Laib S, Bujoli B, Pilet P, Janvier P, et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone. 2005;36(1):52–60.PubMedCrossRef

58.

Peter B, Gauthier O, Laib S, Bujoli B, Guicheux J, Janvier P, et al. Local delivery of bisphosphonate from coated orthopedic implants increases implants mechanical stability in osteoporotic rats. J Biomed Mater Res A. 2006;76(1):133–43.PubMedCrossRef

59.

Stadelmann VA, Gauthier O, Terrier A, Bouler JM, Pioletti DP. Implants delivering bisphosphonate locally increase periprosthetic bone density in an osteoporotic sheep model. A pilot study. Eur Cell Mater. 2008;16:10–6.PubMed

60.

Garbuz DS, Hu Y, Kim WY, Duan K, Masri BA, Oxland TR, et al. Enhanced gap filling and osteoconduction associated with alendronate-calcium phosphate-coated porous tantalum. J Bone Joint Surg Am. 2008;90(5):1090–100.PubMedCrossRef

61.

Gao Y, Luo E, Hu J, Xue J, Zhu S, Li J. Effect of combined local treatment with zoledronic acid and basic fibroblast growth factor on implant fixation in ovariectomized rats. Bone. 2009;44(2):225–32.PubMedCrossRef

62.

Zhou H, Lawrence JG, Touny AH, Bhaduri SB. Biomimetic coating of bisphosphonate incorporated CDHA on Ti6Al4V. J Mater Sci Mater Med. 2012;23(2):365–74.PubMedCrossRef

63.

Kokubo T, Ito S, Huang ZT, Hayashi T, Sakka S, Kitsugi T, et al. Ca, P-rich layer formed on high-strength bioactive glass-ceramic A-W. J Biomed Mater Res. 1990;24(3):331–43.PubMedCrossRef

64.

Yu X, Wei M. Preparation and evaluation of parathyroid hormone incorporated CaP coating via a biomimetic method. J Biomed Mater Res B Appl Biomater. 2011;97(2):345–54.PubMedCrossRef

65.•

Yu X, Wang L, Jiang X, Rowe D, Wei M. Biomimetic CaP coating incorporated with parathyroid hormone improves the osseointegration of titanium implant. J Mater Sci Mater Med. 2012;23(9): 2177–86. Reports effects of PTH (1–34) incorporated into a biomimetic hydroxyapatite coating on titanium implants in non-OVX mice.

66.

Tengvall P, Skoglund B, Askendal A, Aspenberg P. Surface immobilized bisphosphonate improves stainless-steel screw fixation in rats. Biomaterials. 2004;25(11):2133–8.PubMedCrossRef

67.

Roshan-Ghias A, Arnoldi J, Procter P, Pioletti DP. In vivo assessment of local effects after application of bone screws delivering bisphosphonates into a compromised cancellous bone site. Clin Biomech (Bristol, Avon). 2011;26(10):1039–43.CrossRef

68.

Heckman JD, Ryaby JP, McCabe J, Frey JJ, Kilcoyne RF. Acceleration of tibial fracture-healing by non-invasive, low-intensity pulsed ultrasound. J Bone Joint Surg. 1994;76(1):26–34.PubMed

69.

Carvalho DCL, Cliquet A. The action of low-intensity pulsed ultrasound in bones of osteopenic rats. Artif Organs. 2004;28(1):114–8.PubMedCrossRef

70.

Warden SJ, Bennell KL, Forwood MR, McMeeken JM, Wark JD. Skeletal effects of low-intensity pulsed ultrasound on the ovariectomized rodent. Ultrasound Med Biol. 2001;27(7):989–98.PubMedCrossRef

71.

Lim D, Ko C-Y, Seo DH, Woo DG, Kim JM, Chun KJ, et al. Low-intensity ultrasound stimulation prevents osteoporotic bone loss in young adult ovariectomized mice. J Orthop Res. 2011;29(1):116–25.PubMedCrossRef

72.•

Cheung W-H, Chow SK-h, Sun M.-H, Qin L, Leung K-S. Low-intensity pulsed ultrasound accelerated callus formation, angiogenesis and callus remodeling in osteoporotic fracture healing. Ultrasound Med Biol. 2011;37(2):231–8. Reports extensive results of LIPUS treatment following fracture in OVX rats, including bone morphometry and gene expression.

73.

Yoshida A, Sasaki H, Furuya Y, Yoshinari M, Yajima Y. Effect of low-intensity pulsed ultrasound on bone-healing process in murine low-turnover osteoporosis model. J Hard Tissue Biol. 2013;22(3):301–10.CrossRef

74.

Zhao X, Cai X-Z, Shi Z-L, Zhu F-B, Zhao G-S, Yan S-G. Low-Intensity Pulsed Ultrasound (LIPUS) may prevent polyethylene induced periprosthetic osteolysis in vivo. Ultrasound Med Biol. 2012;38(2):238–46.PubMedCrossRef

75.

Aonuma H, Miyakoshi N, Kasukawa Y, Kamo K, Sasaki H, Tsuchie H, et al. Combined treatment of alendronate and low-intensity pulsed ultrasound (LIPUS) increases bone mineral density at the cancellous bone osteotomy site in aged rats: a preliminary study. JNMA; J Nepal Med Assoc. 2011;51(184):171–5.PubMed

76.•

Wang Y, Tran KK, Shen H, Grainger DW. Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials. 2012;33(33): 8540–7. Represents one of the few osteoporosis studies evaluating potential of gene therapy targeting the RANK pathway.

77.

Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25(11):2412–8.PubMedCrossRef

Titel: Local Strategies to Prevent and Treat Osteoporosis
verfasst von: F. Brennan Torstrick
Robert E. Guldberg
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Current Osteoporosis Reports / Ausgabe 1/2014
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-014-0191-6

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Mesenchymal Progenitors and the Osteoblast Lineage in Bone Marrow Hematopoietic Niches

Impact of Inflammation on the Osteoblast in Rheumatic Diseases

Review: Epidemiology and Pathophysiology of Atypical Femur Fractures

Developments in Sclerostin Biology: Regulation of Gene Expression, Mechanisms of Action, and Physiological Functions

Pharmacologic Augmentation of Implant Fixation in Osteopenic Bone